TP53 and colorectal cancer: In colorectal cancer, MA treatment downregulated the expression of E2F transcription factor and induced cell cycle arrest at the G0/G1 phase by decreasing the expression of CDK2/4 and cyclin D1 through the p53/p21/p27 pathways (Lin et al., 2018).